Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee D Kaiser

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|January 3, 2013
Stratification of randomization is not required for a pre-specified subgroup analysisLee D Kaiser
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 23, 2012
Tumor burden modeling versus progression-free survival for phase II decision makingLee D Kaiser
Statistics in Medicine|March 23, 2012
Inefficiency of randomization methods that balance on stratum margins and improvements with permuted blocks and a sequential methodLee D Kaiser
Statistics in Medicine|July 6, 2012
Dynamic randomization and a randomization model for clinical trials dataLee D Kaiser
Contemporary Clinical Trials|January 27, 2011
Analysis of tumor burden versus progression-free survival for Phase II decision makingJane Fridlyand, Lee D Kaiser, Gwen Fyfe
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indicationsLee D Kaiser, Allen S Melemed, Alaknanda J Preston, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|January 3, 2013
Stratification of randomization is not required for a pre-specified subgroup analysisLee D Kaiser
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 23, 2012
Tumor burden modeling versus progression-free survival for phase II decision makingLee D Kaiser
Statistics in Medicine|March 23, 2012
Inefficiency of randomization methods that balance on stratum margins and improvements with permuted blocks and a sequential methodLee D Kaiser
Statistics in Medicine|July 6, 2012
Dynamic randomization and a randomization model for clinical trials dataLee D Kaiser
Contemporary Clinical Trials|January 27, 2011
Analysis of tumor burden versus progression-free survival for Phase II decision makingJane Fridlyand, Lee D Kaiser, Gwen Fyfe
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indicationsLee D Kaiser, Allen S Melemed, Alaknanda J Preston, et al.
Pageof 1